RNS Number : 8512N Uniphar PLC 09 May 2024

AGM Results



Dublin, London | 9 May 2024

Uniphar plc (the **Company**) is pleased to announce that at its Annual General Meeting held at 11.00 a.m. today, 9 May 2024, each of the resolutions set out in the Notice of Annual General Meeting circulated to shareholders and made available on the Company's website, www.uniphar.ie, were duly passed without amendment.

Details of votes cast are set out below:

	RESOLUTION	For	For %	Against	Against %	Withheld
1	Financial Statements					
	and Reports	142,776,909	100	-	0	1,659,778
2	Final Dividend of €3.2m	144,436,687	100	-	0	-
3(a)	Re-elect Ger Rabbette	133,691,402	92.56	10,745,283	7.44	2
3(b)	Re-elect Tim Dolphin	143,757,800	99.53	678,887	0.47	-
3(c)	Re-elect Paul Hogan	143,473,422	99.35	938,265	0.65	25,000
3(d)	Re-elect Sue Webb	144,049,623	99.77	333,788	0.23	53,276
3(e)	Re-elect Jim Gaul	138,288,164	95.78	6,095,247	4.22	53,276
3(f)	Re-elect Liz Hoctor	144,320,340	99.94	91,347	0.06	25,000
3(g)	Re-elect Maurice Pratt	141,968,268	98.29	2,468,417	1.71	2
3(h)	Re-elect Valerie Sick	144,143,411	99.83	240,000	0.17	53,276
4	Remuneration of Auditors	119,304,023	95.49	5,630,519	4.51	19,502,145
5	Authority to allot	110,004,020	30.40	0,000,010	7.01	10,002,140
	relevant securities	125,835,071	87.14	18,573,338	12.86	28,278
6	Disapplication of pre- emption rights in specified circumstances	143,264,607	99.19	1,172,080	0.81	-
7	Disapplication of pre- emption rights in additional circumstances	119,856,072	83.18	24,242,889	16.82	337,726
8	Authorise market purchases of the Company's Ordinary Shares	143,853,843	100	-	0	582,844
9	Re-issuance of Treasury Shares	142,676,687	98.78	1,760,000	1.22	-

--- ENDS ---

Contact Details

Uniphar Group Tel: +353 (0) 1 428 7777

Allan Smylie, Head of Strategy and IR

Davy (Joint Corporate Broker, Nominated Advisor and Euronext Growth Listing Sponsor)

Tel: +353 (0) 1 679 6363

Niall Gilchrist Ivan Murphy

RBC Capital Markets (Joint Corporate Broker)

Tel: +44 (0) 20 7653 4000

Jamil Miah Rupert Walford

Stifel Nicolaus Europe Limited (Joint Corporate Broker) Tel: +44 (0) 20 7710 7600

Matt Blawat Ben Maddison Francis North

Q4 PR Tel: +353 (0) 1 475 1444

larla Mongey, Public Relations Advisor to Uniphar Group

About Uniphar plc

Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA and delivers to 160+ countries.

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.

Uniphar Supply Chain & Retail

Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in Ireland with a growing symbol group offering of retail pharmacies. The Group's strategy for Uniphar Supply Chain & Retail is to grow our wholesale market share, our symbol group network and our own brand, in-licenced and consumer products portfolio.

Uniphar Medtech

Uniphar Medtech is a leading Pan-European medical device distributor and solutions partner. The Group's strategy for Uniphar Medtech is to grow our service offering across Europe and expand our addressable market by serving new specialities and new manufacturers.

Uniphar Pharma

Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they can't source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact msc.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END